Septest Limited

Founded in 2022 by CTO Alistair Wilson and based in UK, Septest Limited operates as a provider of point-of-care diagnostic tests for detecting infections, inflammation, and sepsis in hospital, primary care, and community healthcare settings. As of October 2026, Jag Grewal is the CEO of the company. In March 2026, Septest Limited raised USD 550,000 in pre-seed funding led from Kappika with participation from Oxford Innovation Finance. Septest is a biotechnology and medical diagnostics company developing rapid point-of-care diagnostic tests for the early detection of infections and inflammatory conditions.

Its lead product, TRISEP, is a frontline infection intelligence test designed to provide rapid insight into infection and inflammation in pre-hospital, community, general practice, and hospital settings. The company's solutions focus on improving the diagnosis and management of sepsis, infections, antimicrobial resistance (AMR), pneumonia, tuberculosis, COVID-related conditions, autoimmune diseases, and other inflammatory disorders. Septest aims to provide low-cost, accessible diagnostic tools that enable healthcare professionals to make faster treatment decisions and improve patient outcomes. Septest is currently a pre-commercial medical diagnostics company, so its present funding is likely derived from venture capital, angel investors, innovation grants, accelerator programs, and strategic healthcare partnerships.

Once commercialized, the company is expected to generate revenue through the sale of TRISEP diagnostic tests, point-of-care infection testing kits, diagnostic consumables, healthcare provider contracts, hospital and clinic procurement agreements, and licensing of its diagnostic technologies. Additional revenue opportunities may include partnerships with healthcare systems, distributors, public health agencies, pharmaceutical companies, and global health organizations, along with recurring revenue from diagnostic test usage, device deployment, and infection-monitoring programs. The company's long-term business model is centered on commercializing rapid infection and inflammation diagnostics for hospitals, primary care providers, community healthcare settings, and emerging markets.